Citations

Clear

874 citation(s) found for "Carlson, EE".

Timeliness of antiresorptive consolidation after anabolic therapy for primary fracture prevention: A US cohort study
Badour, Sanaa , McCoy, Rozalina G. , Takagi, Mark, Everhart, Alexander , Parimi, Joseph Theressa Nehu, Herrin, Jeph , Mandic, Pinar Karaca, Wermers, Robert A. , Rosen, Clifford J, Karaca-Mandic, Pinar , Brito, Juan P , McCoy, Rozalina Grubina , Herrin, Jeph , Karaca‐Mandic, Pinar , Rosen, Clifford J. , Brito, Juan P.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | March 3, 2026 | Volume: 111 | Issue: 8 | Pages: 2320-2331

10.1210/clinem/dgag092 | PMID 41778369 Get It

Abstract Context Osteoanabolic therapy for osteoporosis should be followed by antiresorptive treatment (“consolidation”) to preserve bone mass. Although osteoanabolic therapy is increasingly endorsed for primary fracture prevention, real-world implementation of consolidation remains unknown. Objective To assess patterns and predictors of timely consolidation after osteoanabolic therapy for primary fracture prevention. Methods We conducted a retrospective cohort study using US commercial, Medicare Advantage, and traditional Medicare claims data. Adults aged ≥50 years who initiated romosozumab, teriparatide, or abaloparatide between 2011 and 2022 were included. The primary outcome was timely consolidation, defined as initiation of an antiresorptive medication within 3 months after osteoanabolic therapy. Secondary outcomes included delayed consolidation (initiation >3 months after completion), osteoanabolic restart following a treatment gap, and no consolidation therapy. We further distinguished participants who completed the full osteoanabolic course, defined as ≥12 months for romosozumab and ≥18 months for teriparatide or abaloparatide. Multivariable logistic regression models were used to identify predictors of consolidation patterns. Results Among 15 389 patients (mean age 70.6 years; 89% women; 85% White), 30% completed osteoanabolic therapy (median, 12.9 months for romosozumab; 23.4 months for teriparatide/abaloparatide). Overall, 25% had timely consolidation, 24% delayed consolidation, 12% restarted osteoanabolics, and 40% had no consolidation; only 12% completed therapy with timely consolidation. Timely consolidation was more likely with endocrinology (OR 1.31; 95% CI, 1.17-1.48) or rheumatology (OR 1.45; 1.30-1.62) vs primary care, and less likely among patients aged 50-64 years (OR 0.67; 0.58-0.77) vs 65-74, those enrolled in Medicare Advantage (OR 0.85; 0.74-0.98) vs traditional Medicare, or those recently hospitalized (OR 0.88; 0.80-0.97). Odds increased over time (OR 4.27; 3.63-5.05 for 2021 vs 2011 starts). Conclusion Only 1 in 4 patients received timely consolidation therapy after osteoanabolic treatment, and 1 in 8 completed the full sequence. Strategies to improve consolidation in primary fracture prevention are needed.
Parallel Postauricular Incisions: Wound Outcomes of Transmastoid Repair for CSF Leak After Retrosigmoid Vestibular Schwannoma Resection
Obiri-Yeboah, Derrick , Marinelli, John P. , Pais, Alex B., Dang, Danielle , Lohse, Christine M. , Dornhoffer, Jim R., Driscoll, Colin, Carlson, Matthew L., Celda, María Peris, Link, Michael J., Neff, Brian, Gompel, Jamie J. Van, Driscoll, Colin L. W., Carlson, Matthew L. , Neff, Brian A., Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | February 27, 2026 | Volume: 87 | Issue: No issue available | Pages: No page available

10.1055/s-0046-1818740 Get It

Microsurgical Outcomes of Medial Sporadic Vestibular Schwannoma: A Matched Cohort Study of 40 Cases and 120 Referents
Brovold, Brooklyn L., Marinelli, John P. , Lohse, Christine M. , Link, Michael J., Carlson, Matthew L., Link, Michael J. , Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | February 24, 2026 | Volume: 47 | Issue: 5 | Pages: e780-e785

10.1097/mao.0000000000004871 | PMID 41731664 Get It

Objective: To examine microsurgical outcomes of medial sporadic vestibular schwannoma (VS), defined as a spherical tumor within the cerebellopontine angle (CPA) without tubular internal auditory canal (IAC) extension, compared with a referent cohort of “typical” VS with IAC extension. Study design: Historical matched cohort study. Setting: Tertiary referral center. Patients: Forty patients with medial sporadic VS who met the inclusion criteria were each matched to 3 referent patients by age, CPA tumor size, preoperative hearing class, and surgical approach. Interventions: Microsurgical resection. Main outcome measures: Extent of resection, immediate and long-term postoperative facial nerve weakness (House-Brackmann grade >I), and long-term hearing preservation were compared between patients with medial VS and the referent cohort using conditional logistic regression. Results: Medial VS and matched patients with IAC extension were not statistically significantly different in nongross total extent of resection (OR: 1.04, 95% CI: 0.47-2.31), immediate (OR: 0.82, 95% CI: 0.40-1.67) or long-term (OR: 0.59, 95% CI: 0.23-1.48) postoperative facial nerve weakness, or long-term nonserviceable hearing (OR: 0.84, 95% CI: 0.17-4.22). Conclusions: In this matched cohort study of medial VS, we found no statistically significant differences in the extent of resection, facial nerve function, or hearing preservation between tumors with and without IAC extension.
Association of Preoperative Embolization and Vascularization Patterns With Outcomes in Juvenile Nasopharyngeal Angiofibroma Resection
Zalaquett, Nader , Olson, Brennan , Aden, Hafsa D., Stokken, Janalee K., Wiedermann, Joshua P. , Moore, E.J., O'Brien, Erin K., Gompel, J. Van, Brinjikji, W, Cloft, H, Pinheiro‐Neto, Carlos, Gompel, Jamie J. Van , O’Brien, Erin K. , Stokken, Janalee K. , Zalaquett, Nader , Olson, Brennan G , Aden, Hafsa, Eide, Jacob G. , Van Gompel, Jamie J , Cloft, Harry, Pinheiro-Neto, Carlos D , O'Brien, Erin K , Carlson, Matthew L , Brinjikji, W, Cloft, Harry J. , Pinheiro‐Neto, Carlos

Mayo Clinic

Head & Neck | February 19, 2026 | Volume: 48 | Issue: 7 | Pages: 1813-1821

10.1002/hed.70184 | PMID 41709410 Get It

ABSTRACT Background Preoperative vascular embolization (PVE) is commonly used in managing juvenile nasopharyngeal angiofibroma (JNA) to improve outcomes. However, few studies have evaluated how embolization patterns and vascular features affect prognosis. Methods A 15‐year retrospective review was performed on 44 patients with JNA undergoing surgery at one institution. Data included demographics, vascular supply, embolization techniques, surgical outcomes, and recurrence. Results Forty‐three patients underwent PVE. Most tumors were embolized transarterially (93.0%) using polyvinyl alcohol‐based agents (79.1%). The internal maxillary artery was most commonly embolized (93.0%). Internal carotid artery supply was present in 34.9%, and more than two vessels were embolized in 23.3%. Postembolization tumor blush occurred in 60.5%, with a median of 5% of the pre‐embolization blush remaining after embolization. Neither internal carotid involvement, number of vessels embolized, nor residual blush significantly impacted operative time, surgical outcomes, or recurrence. Conclusion With effective embolization, vascular complexity might not affect JNA resection outcomes. Multicenter studies are required to confirm those findings.
Use of a Mixed Reality Headset for Full-Endoscopic Uniportal Interlaminar Resection of a Lumbar Facet Cyst: 2-Dimensional Operative Video
Bathini, Abhijith R., Dubey, Anwesha, Anastasi, Katherine D., Carlson, Brian, Parker, Jonathon J. , Fonseca, Rafael, Porche, Ken, Krishna, Chandan, Bendok, Bernard R., Bathini, Abhijith , Bathini, Abhijith R , Anastasi, Katherine, Bakhsheshian, Joshua , Fonseca, Rafaël , Krishna, Chandan , Bendok, Bernard R.

Mayo Clinic

Operative Neurosurgery | February 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1227/ons.0000000000001949 | PMID 41705978 Get It

Abstract PD4-04: Impact of Polygenic Risk Scores on Breast Cancer Risk Assessment and Clinical Decision Making in Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2: Results from the Prospective Multisite GENRE-2 Clinical Trial
Yadav, Sumeet Kumar, Klassen, Christine L. , Fraker, Jessica , Sahni, Sabrina, Khan, S. A., Khatri, Lakshmi, Vachon, C., Schaid, Daniel J., Sinnwell, J. P., Carlson, E., Hasadsri, Linda , Couch, F. J., Pruthi, Sandhya, Stan, Daniela , Vachon, Celine M. , Sinnwell, Jason P. , Couch, F.J.

Mayo Clinic

Clinical Cancer Research | February 17, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PD4-04-PD4-04

10.1158/1557-3265.sabcs25-pd4-04 Get It

Abstract Background: Incorporation of Polygenic Risk Scores (PRS) can refine traditional breast cancer (BC) risk assessment models to provide precise estimates of BC risk. However, the impact of such an integrated model on BC risk estimates and clinical decision-making related to BC screening and preventive strategies in germline pathogenic variant (PV) carriers is not fully understood. Methods: The GENRE-2 is a prospective single-arm multisite clinical trial (NCT04474834) incorporating 313-PRS into standard BC risk assessment models to determine the impact of PRS on risk estimates and clinical decisions on prevention and screening. All women received pre- and post-PRS BC risk estimates and completed surveys on their screening and cancer prevention decisions before and after integrating PRS estimates. Herein, we report on the impact of integrating PRS into CanRisk-based BC risk estimates among women enrolled in GENRE-2 due to PVs in ATM, BRCA1, BRCA2, CHEK2, or PALB2. Women were categorized into average risk (<20%), moderate risk (20-40%), or high risk (>40%) for BC based on clinically relevant lifetime risk thresholds for supplemental MRI screening and risk-reducing bilateral mastectomies. Changes in categories of lifetime BC risk estimates were then evaluated before and after integration of PRS. Impact of PRS on patient decisions to undertake screening or preventive action (medication or prophylactic mastectomy) was evaluated based on pre- and post-PRS surveys. Results: Between 2020 and 2025, 933 women were enrolled, 633 received PRS results and completed a survey to date. Of those who received PRS results, 214 (33.8%) were PV carriers (ATM: 24, BRCA1: 54, BRCA2: 73, CHEK2: 54 and PALB2: 9). Among PV carriers, the CanRisk-based median 10-year and lifetime pre-PRS risk estimates were 6.0% and 23.9% for ATM, 22.5% and 77.5% for BRCA1, 17.9% and 77.6% for BRCA2, 7.1% and 26.6% for CHEK2, and 16.6% and 42.4% for PALB2, respectively. A total of 7 (29.2%) ATM PV carriers had a shift in lifetime BC risk categories after integration of PRS, with 1 (4.2%) shifting from average to moderate-risk, 3 (12.5%) shifting from moderate to average-risk category, and 3 (12.5%) shifting from moderate to high-risk category. Among CHEK2 PV carriers, 9 (16.7%) had a shift in lifetime risk categories, with 4 (7.4%) shifting from moderate to average-risk, 2 (3.7%) shifting from moderate to high-risk, and 3 (5.6%) shifting from high to moderate-risk. None of the BRCA1 and 4.1% of BRCA2 PV carriers had a shift in lifetime risk categories after PRS integration. Only 1 (11.1%) PALB2 PV carrier had a change in lifetime risk category after integration of PRS, although this was limited by a small sample. A significantly higher proportion of PV carriers with a high lifetime risk intended to take preventative action compared to the PV carriers with average lifetime risk (41.4% vs. 20.0%, p=0.007). Conclusions: Integration of PRS into BC lifetime risk estimates led to a clinically meaningful change in risk categories in 29.2% of ATM PV carriers and 16.7% of CHEK2 PV carriers, but in <5% of BRCA1 or BRCA2 PV carriers. These findings suggest that PRS may be helpful for BC risk stratification in moderate-risk genes such as ATM and CHEK2 but may have limited clinical utility in high-risk genes such as BRCA1 or BRCA2. Citation Format: S. Yadav, C. Klassen, D. Stan, J. Fraker, S. Sahni, S. A. Khan, L. Khatri, C. Vachon, D. Schaid, J. P. Sinnwell, E. Carlson, L. Hasadsri, F. J. Couch, S. Pruthi. Impact of Polygenic Risk Scores on Breast Cancer Risk Assessment and Clinical Decision Making in Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2: Results from the Prospective Multisite GENRE-2 Clinical Trial [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PD4-04.
Factors Affecting Outcomes of Hindfoot Fusion Nails for Acute Injury: A Multicenter Study
Kim, Eugene , Tornetta, Paul , Carlson, Jon, Schultz, Alex, Wireman, Garrett , Ollivere, Benjamin J., Zheng, Amy , Patch, David , White, Tim D. , Heinz, Nicholas , Lahurd, Caroline Elizabeth, Ostrum, Robert F. , Baumann, Charles, Kottmeier, Stephen, Doany, Michael E. , Krause, Peter, Redlich, Nathan, Egol, Kenneth, Konda, Sanjit, Mir, Hassan, McCaskey, Meghan , Azer, Emil, Kusler, Jace E. , Beltran, Michael T., Mehta, Samir, Masada, Kendall M. , Hidden, Krystin A., Kuttner, Nicolas P. , Tornetta, Paul , Beltran, Michael J. , Kuttner, Nicolas, Schultz, Alexander , Ollivere, Ben J. , Zheng, Amy, Spitler, Clay A. , White, Tim, Stinner, Daniel J. , Baumann, Charles A. , Krause, Peter C. , Egol, Kenneth A. , Konda, Sanjit R. , Beltran, Michael, Mehta, Samir D. , Hidden, Krystin A.

Mayo Clinic

Journal of Orthopaedic Trauma | February 13, 2026 | Volume: 40 | Issue: 3 | Pages: 148-154

10.1097/bot.0000000000003104 | PMID 41685944 Get It

OBJECTIVE: To evaluate the effect of joint preparation and patient factors on outcomes and complications in patients treated acutely with hindfoot fusion nails for ankle and pilon fractures. METHODS: Design: Retrospective chart review. Setting: Thirteen US trauma centers and 2 UK trauma centers. Patient Selection Criteria: Ankle and pilon fractures (AO-OTA types A-C) from 2010 to 2020 acutely treated definitively with hindfoot fusion nail were reviewed. Patients at least 18 years old and with minimum 6 months follow-up or earlier diagnosis of complication were included. Exclusion criteria included nonambulatory at baseline, prior internal fixation that failed and underwent revision, and prior tibiotalar or subtalar arthrodesis. Outcome Measurements and Comparisons: The primary outcome was final postoperative ambulatory status. Secondary outcomes were infectious and fracture-related complications. RESULTS: One hundred forty-nine patients (75 men; 74 women; age 20–99; median 63 years) were treated for ankle (104) or pilon (45; 8A, 13B, 24C) fractures. Eighty-five patients (44%) had open fractures and 55 (37%) had diabetes. Thirty-six patients (24%) had joint preparation at the time of surgery. Forty-five (30%) were made weight bearing as tolerated postoperatively; the median time to mobilize was 1.5 days (0–210) and to full weight bearing was 35 days (0–1462). Fifty-seven patients (85%) returned to their preinjury ambulatory status, which was not affected by joint preparation (50% vs. 59%, P = 0.327). Joint preparation led to higher articular fusion rates (94% vs. 24%; P = 0.001) and fewer hardware removals (19% vs. 42%, P = 0.013), but trended toward a higher fracture nonunion rate (19% vs. 8%, P = 0.053). Forty-five patients (30%) had infectious complications, 60 (40%) had a fracture-related complication, and 67 (45%) had additional procedures. Open fractures did not lead to any differences in superficial or deep infection. Insulin-dependent diabetes was associated with higher rates of infectious complications (31% vs. 15%, P = 0.028) and amputation (17% vs. 4%, P = 0.029). CONCLUSIONS: Hindfoot fusion nails for acute ankle and pilon injuries had high complication rates. More complications occurred in patients with insulin-dependent diabetes. While 95% regained ambulation, only 57% returned to preoperative status. Joint preparation led to higher rates of articular fusion (94% vs. 24%, P < 0.001) but not fracture union (81% vs. 66%, P = 0.106). LEVEL OF EVIDENCE: Prognostic Level III. See Instructions for Authors for a complete description of levels of evidence.
Nonconventional Imaging Modalities for Vestibular Schwannoma Prognosis: A Scoping Review
Zalaquett, Nader , Marinelli, John P. , Khandalavala, Karl R. , Lohse, Christine M., Lane, Jack I., Brufau, Santiago-Romero, Huston, John, Carlson, Matthew L., Zalaquett, Nader , Lohse, Christine M. , Chelf, Cynthia , Bathla, Girish , Lane, Jack I., Romero‐Brufau, Santiago , Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | February 13, 2026 | Volume: 47 | Issue: 5 | Pages: 649-656

10.1097/mao.0000000000004863 | PMID 41680977 Get It

Objective: To explore the existing evidence on novel imaging modalities that may aid in prognostication of vestibular schwannoma (VS) clinical outcomes across various management approaches. Study design: Scoping review. Setting: Not applicable. Patients: Individuals diagnosed with VS. Interventions: Novel imaging techniques. Main outcome measures: Tumor growth and response to medical therapy. Results: A total of 18 articles were included in this review. Of these, 7 focused on pretreatment prognosis, 6 evaluated radiosurgery outcomes, 4 examined microsurgery outcomes, and 1 assessed response to bevacizumab. The imaging modalities investigated included radiomics (n = 10), positron emission tomography (PET; n = 2), dynamic contrast-enhanced MRI (DCE-MRI; n = 2), both PET and DCE-MRI (n = 1), magnetic resonance elastography (MRE; n = 1), contrast-enhanced CT (CE-CT; n = 1), and slip interface imaging (SII; n = 1). Radiomic studies yielded encouraging results in predicting tumor growth after wait-and-scan and radiosurgery, with reported accuracies ranging from 52% to 88%, sensitivities from 13% to 95%, specificities from 50% to 94%, and area under the curves from 0.65 to 0.99. PET studies identified several promising ligands associated with tumor growth during wait-and-scan, suggesting a potential role in prognostication. DCE-MRI also demonstrated associations with tumor growth and treatment response to bevacizumab. Studies on MRE, CE-CT, and SII identified novel imaging parameters associated with tumor stiffness and adhesion. Conclusions: Several emerging imaging modalities hold potential for improving clinical outcome prognostication in VS. Techniques such as radiomics, PET, and DCE-MRI have shown promising results; however, the supporting evidence is still limited and heterogeneous. Further research is necessary to validate and refine these approaches to enhance their clinical utility.
A Pilot Validation Study of Plant‐Based and Allergy‐Friendly Alternative for Testing Gastric Emptying: A Randomized Trial in Healthy Participants
Abdelnaem, Nada, Carlson, Paula, Busciglio, Irene, Burton, Duane, Ryks, Michael, Johnson, Derek R., Navin, Patrick J. , Bach, Corrie R. , Paulsen, Andrew, Bartlett, David J. , Camilleri, M., Jencks, Kara J. , Bach, Corrie, Paulsen, Andrew M, Camilleri, M , Navin, Patrick , Ryks, Michael, Johnson, Derek R., Camilleri, Michael

Mayo Clinic

Neurogastroenterology & Motility | February 13, 2026 | Volume: 38 | Issue: 2 | Pages: No page available

10.1111/nmo.70268 | PMID 41681033 Get It

ABSTRACT Background Gastric emptying (GE) scintigraphy with 4‐h imaging and a radiolabeled chicken egg‐based meal (320 kcal, 30% fat) is the standard test for gastroparesis at Mayo Clinic, with an intraindividual coefficient of variation (COV intra ) of 23.8% for GE half emptying time (T 1/2 ). Alternative meals for patients with dietary restrictions, including egg allergies or vegan diets, are lacking, limiting test accessibility. The study aimed to establish a vegan, lactose‐, nut‐, and gluten‐free meal with similar caloric and fat content to the egg meal and to assess its performance in GE studies. Methods In Vitro: 99m Tc binding to egg meal over 4 h was compared to a calorically and nutritionally similar vegan alternative, JUST Egg, using a validated in vitro model simulating gastric conditions of pH, pepsin, and stirring. In Vivo: 10 healthy participants underwent randomized crossover GE scintigraphy with standard and vegan meals, spaced ≥ 3 days apart to measure GE% at 2 h, 4 h, and GE T 1/2 . Group comparisons and variance analysis included Rank Sum tests and Bland–Altman plots. Key Results In Vitro: A strong correlation ( R = 0.975, p ‐value < 0.01) between 99m Tc binding in the egg and vegan egg models was observed. Minimal variance (< 10%) was recorded at all time points. In Vivo: GE at 4 h and GE T 1/2 showed non‐statistically significant mean differences, < 2% and < 10 min respectively, between both meals. The intra‐individual variability was 18.8%. Conclusions and Inferences The vegan meal demonstrated in vitro stability, in vivo performance comparable to the egg meal, and a COV intra of 18.8%, which was lower than the 23.8% reported in repeat egg meal GE studies. Trial Registration ClinicalTrials.gov number NCT06991036 ( https://clinicaltrials.gov/study/NCT06991036?term=NCT06991036&rank=1 )
Loudness Adaptation Among Cochlear Implant Candidates to Inform Hearing Preservation During Awake Cochlear Implantation
Khandalavala, Karl R. , Lohse, Christine M. , Gruenwald, Jill M., Thompson, Ember S., Bross, Abigail E., Kirtz, Ashlee P., Carlson, Matthew L., Bross, Abigail E., Carlson, Matthew L.

Mayo Clinic

Otology & Neurotology | February 11, 2026 | Volume: 47 | Issue: 3 | Pages: 423-426

10.1097/mao.0000000000004814 | PMID 41668269 Get It

Objective: Cochlear implantation (CI) under local anesthesia facilitates intraoperative behavioral patient feedback to potentially improve acoustic hearing preservation and limit intracochlear trauma. Patient feedback during electrode insertion is potentially confounded by loudness adaptation, a perception of tone decrease despite stable presentation, or insufficient intensity discrimination, a failure to detect a change in hearing despite one actually occurring. Both loudness adaptation and intensity discrimination are critical factors for awake CI and have not been systematically studied in the CI candidate population. Patients: Adult candidates for CI. Interventions: Under routine audiometric testing conditions in a soundproof booth, a standard behavioral audiogram, audiogram obtained in recorded ambient operating room (OR) noise, loudness adaptation to sustained suprathreshold (+10 and +20 dB) pure tones at 500, 1000, 2000, and 4000 Hz in both quiet and in ambient OR noise, and intensity discrimination to sustained suprathreshold (+10 and +20 dB) pure tones at 500, 1000, 2000, and 4000 Hz were performed. Main outcome measures: Pure tone average (PTA) in quiet and in ambient OR noise, proportion of patients reporting loudness adaptation at different suprathreshold levels and frequencies, and reliability of intensity discrimination. Results: In total, 20 ears were included for study. The median PTA was similar between testing in quiet (68 dB, IQR: 63 to 73) and in ambient OR noise (68 dB, IQR: 62 to 73). Most participants (n = 11, 55%) reported loudness adaptation when testing at +10 dB suprathreshold intensity, with a decreased proportion (n = 8, 40%) demonstrating adaptation at the higher tone intensity (+20 dB suprathreshold). Loudness adaptation varied among frequencies, with a trend toward increasing adaptation at higher frequencies at both testing intensities. Participants demonstrated excellent intensity discrimination, detecting a 5 dB difference when testing at +10 dB both in quiet and with background OR noise in 82 of the 85 (96%) tests performed across the frequency range, although with lower intensity discrimination at +20 dB, particularly in background OR noise. Conclusions: For CI candidates, pure tone audiometric performance did not significantly differ in background OR noise, confirming the reliability of intraoperative audiometric testing. For optimal tone presentation, there is decreasing loudness adaptation with increased tone presentation (+20 dB suprathreshold) and in lower frequencies of tone presentation. Intensity discrimination was reliable at a 5 dB increment across a range of testing parameters.